Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A twenty six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo compared to standard of care insulin for initiating basal insulin in insulin naïve patients with uncontrolled type 2 diabetes mellitus, with 6 month extension

Next Previous
Trial Profile

A twenty six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo compared to standard of care insulin for initiating basal insulin in insulin naïve patients with uncontrolled type 2 diabetes mellitus, with 6 month extension

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin; Insulin degludec; Insulin detemir
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms REACH; REACH CONTROL
  • Sponsors Sanofi

Most Recent Events

  • 25 Sep 2020 Results from real-world studies ACHIEVE, REACH, REGAIN, and RCTs EDITION 1-3 and BRIGHT assessing Treatment satisfaction in people with type 2 diabetes receiving basal insulin, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
  • 28 Oct 2017 This trial has been completed in Spain.
  • 27 Oct 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top